The development of cancer is a multi-step process involving DNA alterations, oncogene activation, and/or the inactivation/deletion of an anti-onocogene or tumor suppressor. Tumor suppressors are involved in many facets of cell biology,such as cell cycle regulation and development. FEZ1 (F37/Esophageal cancer related gene-coding leucine zipper motif) is a putative DNA-binding protein with homology to cAMP-responsive activating-transcription factor 5 (Atf-5). The structure of FEZ1 includes DNA-binding and leucine zipper domains at amino acids 301-369 , as well as a putative cAMP-dependent phosphorylation site at Ser-29. FEZ1 is ubiquitously expressed in normal tissues with the most abundant expression in testes and brain, but is absent in 31 different cancer cell lines and 16 primary tumors. In addition, the FEZ1 gene has missense mutations in two primary esophageal cancers and a nonsense mutation in a prostate cancer cell line. Several FEZ1-expressing tumors have internally truncated FEZ1 mRNA transcripts. Thus, FEZ1 inactivation in cancers may involve both allelic loss and point mutations and implicates FEZ1 in cAMP-dependent tumor suppression.
This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.